Publications

Back to Publications

Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.

The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized For Acute Heart Failure: A Multinational Randomized Trial

Nature Med 2022;28:568–74 doi: 10.1038/s41591-021-01659-1

Empagliflozin reduces the risk of cardiovascular death or heart failure hospitalisation in patients with chronic heart failure, however, it is unknown whether empagliflozin improves clinical outcomes when initiated in patients who are hospitalised for acute heart failure. Voors et al. investigate this in a double-blind trial.


LinkedIn